There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY – Research Report) and Reneo Pharmaceuticals (RPHM – Research Report) with bullish sentiments.
Alnylam Pharma (ALNY)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Alnylam Pharma, with a price target of $254.00. The company’s shares closed last Monday at $168.32, close to its 52-week low of $167.40.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $246.94, a 45.5% upside from current levels. In a report issued on September 28, Raymond James also initiated coverage with a Buy rating on the stock with a $208.00 price target.
See the top stocks recommended by analysts >>
Reneo Pharmaceuticals (RPHM)
In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Buy rating on Reneo Pharmaceuticals, with a price target of $23.00. The company’s shares closed last Monday at $8.37.
According to TipRanks.com, Zemansky is a 2-star analyst with an average return of
Currently, the analyst consensus on Reneo Pharmaceuticals is a Strong Buy with an average price target of $27.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNY:
- FDA PDUFA Date for Alnylam Patisiran (Onpattro) is October 8, 2023
- Alnylam initiated with Outperform on ‘robust’ pipeline at Raymond James
- Alnylam initiated with an Outperform at Raymond James
- Alnylam should be bought on recent selloff, says H.C. Wainwright
- Concerns over label expansion for Alnylam overdone, says Citi
